Insmed INSM
NASDAQ INSM
$126.29 -0.39 (-0.31%)
At close: Sep 4, 2026 · 4:00 PM EDT

Insmed (INSM) Non-Current Debt (2012 - 2026)

Insmed (INSM) posted Non-Current Debt of $546.8 million for Q2 2026, little changed on a QoQ basis from $546.8 million in Q1 2026, and little changed year-over-year from $546.8 million in Q2 2025.

Analysis

Insmed (INSM) Non-Current Debt (2012 - 2026) Analysis & Trends

Insmed has reported Non-Current Debt for 15 years, with the latest figure at $546.8 million in Q2 2026.

  • On a quarterly basis, Non-Current Debt changed 0.0% year-over-year to $546.8 million in Q2 2026; TTM through Jun 2026 was $546.8 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $541.0 million, down 50.97% from the prior year.
  • Non-Current Debt was $546.8 million for Q2 2026 at Insmed, roughly flat from $546.8 million in the prior quarter.
  • The five-year high for Non-Current Debt was $1.2 billion in Q2 2024, with the low at $541.0 million in Q4 2025.
  • Average Non-Current Debt over 5 years is $915.3 million, with a median of $1.0 billion recorded in 2024.
  • The sharpest annual moves came in 2022 and 2025: Non-Current Debt soared 98.6% in 2022, then tumbled 54.06% in 2025.
  • Over 5 years, Non-Current Debt stood at $1.1 billion in 2022, then grew by 2.67% to $1.2 billion in 2023, then declined by 4.49% to $1.1 billion in 2024, then sank by 50.97% to $541.0 million in 2025, then climbed by 1.07% to $546.8 million in 2026.
  • The last three Non-Current Debt figures came in at $546.8 million (Q2 2026), $546.8 million (Q1 2026), and $541.0 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 57.30 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 26.25 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 1.99 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 591.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn -
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 7.29 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 546.77 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn 124.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 546.77 Mn
Mar 31, 2026 546.77 Mn
Dec 31, 2025 540.96 Mn
Sep 30, 2025 546.77 Mn
Jun 30, 2025 546.77 Mn
Mar 31, 2025 1.12 Bn
Dec 31, 2024 1.10 Bn
Sep 30, 2024 971.76 Mn
Jun 30, 2024 1.19 Bn
Mar 31, 2024 1.18 Bn
Dec 31, 2023 1.16 Bn
Sep 30, 2023 1.17 Bn
Jun 30, 2023 1.17 Bn
Mar 31, 2023 1.16 Bn
Dec 31, 2022 1.13 Bn
Sep 30, 2022 800.00 Mn
Jun 30, 2022 800.00 Mn
Mar 31, 2022 800.00 Mn
Dec 31, 2021 566.59 Mn
Sep 30, 2021 800.00 Mn